EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial

Ana Oaknin, Bradley J Monk, Andreia Cristina de Melo, Hee Seung Kim, Yong Man Kim, Alla S Lisyanskaya, Vanessa Samouëlian, Domenica Lorusso, Fernanda Damian, Chih-Long Chang, Evgeniy Gotovkin, Shunji Takahashi und 22 weitere

European Journal of Cancer · 2025-02 · 216 · 115146

DOI: 10.1016/j.ejca.2024.115146 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2025-02. Verfasst von Ana Oaknin und 33 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Electronic address: aoaknin…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Antibodies, Monoclonal, Humanized, Neoplasm Recurrence, Local, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: Cemiplimab has demonstrated significantly longer survival than physician's choice of chemotherapy in patients with recurrent cervical cancer after first-line platinum-containing chemotherapy. We report the final survival analysis from the phase III randomized study (EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9). METHODS: Cemiplimab (n = 304) or chemotherapy (n = 304) were administered every 3 weeks. The primary endpoint was overall survival (OS). Patients were included regardless of programmed cell death-ligand 1 (PD-L1) status. RESULTS: At a median follow-up of 47.3 months (data cut-off: April 20, 2023), median OS was 11.7 versus 8.5 months for patients treated with cemiplimab and chemotherapy, respectively (hazard ratio 0.67, 95 % confidence interval 0.56-0.80, p < .00001). OS benefit was seen in PD-L1 positive and negative populations, even though more patients with PD-L1 < 1 % (n = 92), had poor performance status in the cemiplimab arm than the chemotherapy arm (61.4 % vs 47.9 %). CONCLUSION: This final analysis confirms that cemiplimab maintains survival benefit compared with chemotherapy in recurrent cervical cancer after progression on first-line platinum therapy, regardless of PD-L1 expression. The safety profile was consistent with published data; incidences of adverse events were similar between cemiplimab and chemotherapy groups. These results support the use of second-line cemiplimab for patients with recurrent cervical cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsAntibodies, Monoclonal, HumanizedNeoplasm Recurrence, LocalAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAdultAgedB7-H1 Antigen

Stichwörter der Autor:innen

CemiplimabCervical cancerImmunotherapyPD-1

Substanzen

Antibodies, Monoclonal, HumanizedcemiplimabAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Electronic address: aoaknin@vhio.net.
  • Florida Cancer Specialists and Research Institute, West Palm Beach, FL, USA.
  • Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, Rio de Janeiro, Brazil.
  • Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea.
  • Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan, Seoul, South Korea.
  • Department of Gynecology, St. Petersburg State Budgetary Healthcare Institution "City Oncological Dispensary", St. Petersburg, Russia.

Förderung

  • Regeneron Pharmaceuticals

Zitieren

APA

Oaknin, A., Monk, B. J., de Melo, A. C., Kim, H. S., Kim, Y. M., Lisyanskaya, A. S., Samouëlian, V., Lorusso, D., Damian, F., Chang, C. L., Gotovkin, E., Takahashi, S., Ramone, D., Maćkowiak-Matejczyk, B., Polastro, L., Alia, E. M. G., Colombo, N., Makarova, Y., Goh, J. C., …, & Tewari, K. S. (2025). Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. European Journal of Cancer, 216, 115146. https://doi.org/10.1016/j.ejca.2024.115146

Vancouver

Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, et al. Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. European Journal of Cancer. 2025;216:115146. doi:10.1016/j.ejca.2024.115146

BibTeX
@article{Oaknin2025,
  author = {Oaknin, Ana and Monk, Bradley J and de Melo, Andreia Cristina and Kim, Hee Seung and Kim, Yong Man and Lisyanskaya, Alla S and Samouëlian, Vanessa and Lorusso, Domenica and Damian, Fernanda and Chang, Chih-Long and Gotovkin, Evgeniy and Takahashi, Shunji and Ramone, Daniella and Maćkowiak-Matejczyk, Beata and Polastro, Laura and Alia, Eva Maria Guerra and Colombo, Nicoletta and Makarova, Yulia and Goh, Jeffrey C and Hasegawa, Kosei and Mora, Paulo and Pikiel, Joanna and Srivastav, Ratnesh and Rischin, Danny and Rubio, Maria Jesús and Perez, Javier and Yoo, Suk Young and Gao, Bo and Jamil, Shaheda and Seebach, Frank and Lowy, Israel and Mathias, Melissa and Fury, Matthew G and Tewari, Krishnansu S},
  title = {Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {216},
  pages = {115146},
  doi = {10.1016/j.ejca.2024.115146}
}
Kostenlos starten →